Samsara Biocapital, Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$1.03B
Q ending 2026-03-31
Prior quarter
$969.3M
Q ending 2025-12-31
Change
+6.2% QoQ · +83.5% YoY
Positions
22
reported holdings
Largest positions
All 22 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Scholar Rock Hldg Corp | SRRK | Shares | $339.1M | 6.9M |
| Mineralys Therapeutics Inc | MLYS | Shares | $159.0M | 5.9M |
| Alumis Inc | ALMS | Shares | $139.8M | 6.3M |
| Septerna Inc | SEPN | Shares | $75.7M | 3.1M |
| Kalaris Therapeutics Inc | KLRS | Shares | $74.7M | 12.9M |
| Spyglass Pharma Inc | SGP | Shares | $54.7M | 2.1M |
| Neurogene Inc | NGNE | Shares | $34.6M | 1.7M |
| Inventiva Sa | IVA | Shares | $28.8M | 5.2M |
| Sutro Biopharma Inc | STRO | Shares | $26.5M | 1.1M |
| Jade Biosciences Inc | JBIO | Shares | $13.6M | 969K |
| Vtv Therapeutics Inc | VTVT | Shares | $11.8M | 298K |
| Aquestive Therapeutics Inc | AQST | Shares | $10.4M | 2.5M |
| X4 Pharmaceuticals Inc | XFOR | Shares | $7.6M | 1.8M |
| Nkarta Inc | NKTX | Shares | $7.4M | 3.5M |
| Arcellx Inc | ACLX | Shares | $7.0M | 61K |
| Upstream Bio Inc | UPB | Shares | $6.6M | 736K |
| Abivax Sa | ABVX | Shares | $6.3M | 57K |
| Agomab Therapeutics Nv | AGMB | Shares | $6.3M | 600K |
| Rani Therapeutics Hldgs Inc | RANI | Shares | $6.2M | 8.5M |
| Coherus Oncology Inc | CHRS | Shares | $5.8M | 3.4M |
| Palvella Therapeutics Inc Ne | PVLA | Shares | $4.8M | 38K |
| Gossamer Bio Inc | GOSS | Shares | $2.4M | 7.2M |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.